Medicalgorithmics, a leading medical technology company listed on the sWIG80 index, has received CE certification for the next generation of its artificial intelligence algorithms, DeepRhythmAI (DRAI), used for analyzing heart ECG data. The new version of DRAI was previously approved for use in the US market by the FDA in 2022. Its commercial use will significantly strengthen the company’s position in the arrhythmia diagnostics market.
DeepRhythmAI is a set of innovative algorithms designed for ECG signal analysis. Developed by a team of Medicalgorithmics experts in collaboration with leading scientific centers and opinion leaders from Europe, Canada, and the USA, DRAI is used both in scientific research and procedures requiring ECG signal analysis. These algorithms enable more accurate arrhythmia diagnostics, contributing to improved patient care.
“DeepRhythmAI is a unique solution due to the use of advanced machine learning and artificial intelligence technology, which allows for significantly better data analysis results. The new generation of DRAI not only increases diagnostic accuracy but also complies with the latest AI Act regulations, which are now in force in the European Union. We continuously monitor AI regulations and incorporate them into our R&D and certification processes,” said Przemysław Tadla, CTO of Medicalgorithmics.
One of the greatest advantages of DeepRhythmAI is its very high analysis accuracy, eliminating the need for an ECG technician. The entire process is fully automatic and does not require human involvement in preparing a Holter study report. Thanks to DRAI, the time needed to generate a Holter study report is reduced by 50% compared to the company’s currently offered PCClient software. Additionally, DRAI is designed for integration with third-party software, allowing for its wide application in various diagnostic systems.
The new generation of AI algorithms will help Medicalgorithmics attract new clients. The company will be able to offer DeepRhythmAI as a standalone product alongside the comprehensive AI PCClient system and PocketECG heart monitoring devices. This flexibility allows the medtech company to tailor its offerings to client needs. Some new partners in the USA, with whom the company began commercial cooperation this year, are already using DeepRhythmAI.
“Our advanced AI algorithms significantly accelerate the ECG data analysis process, enhancing its quality. DRAI greatly increases the productivity of ECG technicians, enabling them to prepare more diagnostic reports for more patients at the same time. This is crucial in reducing the operational costs for hospitals and service providers, such as IDTFs in the USA, and also shortens the patient’s wait time for diagnostic results, speeding up potential therapy that a doctor can undertake. With CE certification, we can now introduce DRAI to European markets, offering our clients a reliable and modern diagnostic tool also as a standalone product that we can integrate with other software. This expansion of our product offering is a key element in our strategy to increase sales and restore the company’s profitability,” said Jarosław Jerzakowski, Member of the Management Board of Medicalgorithmics for Sales and Operations (COO).
Medicalgorithmics has been conducting advanced R&D on artificial intelligence algorithms for years, collaborating with leading scientific centers and experts worldwide. Obtaining CE certification for DRAI is another step in the company’s mission to provide innovative medical solutions that improve patients’ quality of life globally. The company supplies non-invasive cardiology diagnostic software that uses AI algorithms to clients worldwide. Medicalgorithmics offers its arrhythmia diagnostic system and integrated ECG monitoring devices, including the PocketECG device. The company’s solutions reduce the labor involved in describing and generating ECG study reports and can detect and describe 26 types of heart rhythm disorders, placing them among the world leaders.